Heron Therapeutics (HRTX) Cash from Financing Activities (2010 - 2026)
Heron Therapeutics (HRTX) reported Cash from Financing Activities of -$51000.0 for Q1 2026, down 179.69% on a YoY basis from $64000.0 in Q1 2025, and down 123.29% quarter-over-quarter from $219000.0 in Q4 2025.
Heron Therapeutics (HRTX) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Heron Therapeutics has reported Cash from Financing Activities for 17 years, with the latest figure at -$51000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Financing Activities fell 179.69% year-over-year to -$51000.0; the trailing twelve-month figure through Mar 2026 stood at $14.3 million (up 1341.29% YoY), and the FY2025 full-year result was $14.4 million, up 1434.79% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at -$51000.0, down from $219000.0 in the prior quarter.
- The five-year high for Cash from Financing Activities was $74.9 million in Q3 2022, with the low at -$637000.0 in Q1 2022.
- Historically, Cash from Financing Activities has averaged $8.5 million across 5 years, with a median of $315000.0 in 2022.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities soared 105652.11% — and 2026, when it plunged 179.69%.
- Heron Therapeutics' Cash from Financing Activities stood at $439000.0 in 2022, then slumped by 54.67% to $199000.0 in 2023, then jumped by 112.56% to $423000.0 in 2024, then tumbled by 48.23% to $219000.0 in 2025, then sank by 123.29% to -$51000.0 in 2026.
- The last three Cash from Financing Activities figures came in at -$51000.0 (Q1 2026), $219000.0 (Q4 2025), and $13.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 53,000.00 |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 85,464.43 |
| 10 | Heron Therapeutics | 85.57 Mn | 55.60 Mn | 24.07 Mn | -51,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -51,000.00 |
| Mar 31, 2026 | -51,000.00 |
| Dec 31, 2025 | 219,000.00 |
| Dec 31, 2025 | 219,000.00 |
| Sep 30, 2025 | 13.36 Mn |
| Sep 30, 2025 | 13.36 Mn |
| Jun 30, 2025 | 781,000.00 |
| Jun 30, 2025 | 781,000.00 |
| Mar 31, 2025 | 64,000.00 |
| Mar 31, 2025 | 64,000.00 |
| Dec 31, 2024 | 423,000.00 |
| Dec 31, 2024 | 423,000.00 |
| Sep 30, 2024 | 14,000.00 |
| Sep 30, 2024 | 14,000.00 |
| Jun 30, 2024 | 492,000.00 |
| Jun 30, 2024 | 492,000.00 |
| Mar 31, 2024 | 11,000.00 |
| Mar 31, 2024 | 11,000.00 |
| Dec 31, 2023 | 199,000.00 |
| Dec 31, 2023 | 199,000.00 |